-
1
-
-
0036273331
-
Alkylating agents and nucleoside analogs in the treatment of B-cell chronic lymphocityc leukemia
-
Robak T, Kasznicki M. Alkylating agents and nucleoside analogs in the treatment of B-cell chronic lymphocityc leukemia. Leukemia 2002;16:1015-1027.
-
(2002)
Leukemia
, vol.16
, pp. 1015-1027
-
-
Robak, T.1
Kasznicki, M.2
-
2
-
-
0034649696
-
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
-
Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-1757.
-
(2000)
N Engl J Med
, vol.343
, pp. 1750-1757
-
-
Rai, K.R.1
Peterson, B.L.2
Appelbaum, F.R.3
-
3
-
-
51649093353
-
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
-
Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-980.
-
(2008)
Blood
, vol.112
, pp. 975-980
-
-
Tam, C.S.1
O'Brien, S.2
Wierda, W.3
-
4
-
-
0031670669
-
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients
-
Cheson BD Sorensen JM Vena DA et al.Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients.J Clin Oncol.1998:16:3007-3015
-
(1998)
J Clin Oncol
, vol.16
, pp. 3007-3015
-
-
Cheson, B.D.1
Sorensen, J.M.2
Vena, D.A.3
-
5
-
-
4444288930
-
An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine
-
Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476-1481.
-
(2004)
Leukemia
, vol.18
, pp. 1476-1481
-
-
Jehn, U.1
Bartl, R.2
Dietzfelbinger, H.3
Haferlach, T.4
Heinemann, V.5
-
6
-
-
22044444135
-
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience
-
Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005;106:241-246.
-
(2005)
Blood
, vol.106
, pp. 241-246
-
-
Chadha, P.1
Rademaker, A.W.2
Mendiratta, P.3
-
7
-
-
0034063889
-
Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia - updated results of the multicentre study of 378 patients
-
Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia - updated results of the multicentre study of 378 patients. Br J Haematol 2000;108:357-368.
-
(2000)
Br J Haematol
, vol.108
, pp. 357-368
-
-
Robak, T.1
Bloński, J.Z.2
Kasznicki, M.3
-
8
-
-
0034667537
-
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial
-
Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96:2723-2729.
-
(2000)
Blood
, vol.96
, pp. 2723-2729
-
-
Robak, T.1
Bloński, J.Z.2
Kasznicki, M.3
-
9
-
-
77955448467
-
Randomized comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy in chronic lymphocytic leukaemia: Updated results of PALGCLL3 trial
-
Robak T, Blonski JZ, Gora-Tybor J, et al. Randomized comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy in chronic lymphocytic leukaemia: updated results of PALGCLL3 trial. Leuk Lymphoma 2007;48(Suppl.): 162.
-
(2007)
Leuk Lymphoma
, vol.48
, Issue.SUPPL.
, pp. 162
-
-
Robak, T.1
Blonski, J.Z.2
Gora-Tybor, J.3
-
10
-
-
72149085331
-
Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukaemia (CLL). First results from the International Randomized Phase III trial
-
(Abstract 630)
-
Karlsson KA, Strömberg M, Jönsson V, Mulligan SP, Liliemark J, Juliusson G. Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukaemia (CLL). First results from the International Randomized Phase III trial. Blood 2007;110(Suppl. 1):194a (Abstract 630).
-
(2007)
Blood
, vol.110
, Issue.SUPPL. 1
-
-
Karlsson, K.A.1
Strömberg, M.2
Jönsson, V.3
Mulligan, S.P.4
Liliemark, J.5
Juliusson, G.6
-
11
-
-
0037108822
-
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma
-
Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;15: 4261-4267.
-
(2002)
J Clin Oncol
, vol.15
, pp. 4261-4267
-
-
Hainsworth, J.D.1
Litchy, S.2
Burris III, H.A.3
-
12
-
-
0034796371
-
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity to either drug alone
-
Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity to either drug alone. Br J Haematol 2001;114:800-809.
-
(2001)
Br J Haematol
, vol.114
, pp. 800-809
-
-
Di Gaetano, N.1
Xiao, Y.2
Erba, E.3
-
13
-
-
19944429446
-
Addition of rituximab to fludarabine may prolong progression free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: in an updated retrospective analysis of CALGB 9712 and CALGB 9011
-
Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: in an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105:49-53.
-
(2005)
Blood
, vol.105
, pp. 49-53
-
-
Byrd, J.C.1
Rai, K.2
Peterson, B.L.3
-
14
-
-
33749600951
-
Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma
-
Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski JZ. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006;107:1542-1550.
-
(2006)
Cancer
, vol.107
, pp. 1542-1550
-
-
Robak, T.1
Smolewski, P.2
Cebula, B.3
Szmigielska-Kaplon, A.4
Chojnowski, K.5
Blonski, J.Z.6
-
15
-
-
58149331063
-
Expression of the human concentrative nucleotide transporter (hCNT1) gene correlates with clinical response in patients affected by Waldenstrom's macroglobulinemia (WM), undergoing a combination treatment with cladribine (2-CdA) and rituximab
-
(Abstract 1357)
-
Laszlo D, Rabascio C, Andreola G, et al. Expression of the human concentrative nucleotide transporter (hCNT1) gene correlates with clinical response in patients affected by Waldenstrom's macroglobulinemia (WM), undergoing a combination treatment with cladribine (2-CdA) and rituximab. Blood 2007;110(Suppl. 1):408a (Abstract 1357).
-
(2007)
Blood
, vol.110
, Issue.SUPPL. 1
-
-
Laszlo, D.1
Rabascio, C.2
Andreola, G.3
-
16
-
-
0029981025
-
National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
-
Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
-
(1996)
Blood
, vol.87
, pp. 4990-4997
-
-
Cheson, B.D.1
Bennett, J.M.2
Grever, M.3
-
18
-
-
0037406968
-
ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia
-
Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia. N Eng J Med 2003;348:1764- 1775.
-
(2003)
N Eng J Med
, vol.348
, pp. 1764-1775
-
-
Crespo, M.1
Bosch, F.2
Villamor, N.3
-
19
-
-
34247594390
-
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukemia
-
Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukemia. Leukemia 2007;21:956-964.
-
(2007)
Leukemia
, vol.21
, pp. 956-964
-
-
Rawstron, A.C.1
Villamor, N.2
Ritgen, M.3
-
20
-
-
45149100665
-
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: Aa report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute- Working Group 1996 guidelines
-
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood 2008;111:5446-5456.
-
(2008)
Blood
, vol.111
, pp. 5446-5456
-
-
Hallek, M.1
Cheson, B.D.2
Catovsky, D.3
-
21
-
-
61849091076
-
Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and R (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL)
-
(Abstract 325)
-
Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and R (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl. 1):125 (Abstract 325).
-
(2008)
Blood
, vol.112
, Issue.SUPPL. 1
, pp. 125
-
-
Hallek, M.1
Fingerle-Rowson, G.2
Fink, A.M.3
-
22
-
-
62549117867
-
Preliminary results of the combination rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) followed by rituximab maintenance in prevously untreated chronic lymphocytic leukemia (CLL)
-
(Abstract 626)
-
Bosch F, Muntanola A, Villamor N, et al. Preliminary results of the combination rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) followed by rituximab maintenance in prevously untreated chronic lymphocytic leukemia (CLL). Blood 2007;110(Suppl. 1):193a (Abstract 626).
-
(2007)
Blood
, vol.110
, Issue.SUPPL. 1
-
-
Bosch, F.1
Muntanola, A.2
Villamor, N.3
-
23
-
-
0026347961
-
2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia
-
Saven A, Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 1991;5(Suppl. 1):133-138.
-
(1991)
Leuk Lymphoma
, vol.5
, Issue.SUPPL. 1
, pp. 133-138
-
-
Saven, A.1
Carrera, C.J.2
Carson, D.A.3
-
24
-
-
0027465143
-
High complete remission rate from 2-chlordeoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease in blood lymphocyte count
-
Juliusson G, Liliemark J. High complete remission rate from 2-chlordeoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease in blood lymphocyte count. J Clin Oncol 1993;11:679-689.
-
(1993)
J Clin Oncol
, vol.11
, pp. 679-689
-
-
Juliusson, G.1
Liliemark, J.2
-
25
-
-
0030018146
-
Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia
-
Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol 1996;7:373-379.
-
(1996)
Ann Oncol
, vol.7
, pp. 373-379
-
-
Juliusson, G.1
Liliemark, J.2
-
26
-
-
0028945716
-
2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia
-
Saven A, Lemon RH, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995;13:570-574.
-
(1995)
J Clin Oncol
, vol.13
, pp. 570-574
-
-
Saven, A.1
Lemon, R.H.2
Kosty, M.3
-
27
-
-
1842588045
-
Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies
-
Robak T, Smolewski P, Urbanska-Rys H, Gora-Tybor J, Blonski JZ, Kasznicki M. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma 2004;45:937-944.
-
(2004)
Leuk Lymphoma
, vol.45
, pp. 937-944
-
-
Robak, T.1
Smolewski, P.2
Urbanska-Rys, H.3
Gora-Tybor, J.4
Blonski, J.Z.5
Kasznicki, M.6
-
28
-
-
0029956950
-
Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia
-
Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996;14:2160-2166.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2160-2166
-
-
Juliusson, G.1
Christiansen, I.2
Hansen, M.M.3
-
29
-
-
0027056958
-
On the bioavailability of oral and subcutaneous 2-chloro-20- deoxyadenosine in humans: Alternative routes of administration
-
Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-20-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992;10:1514-1518.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1514-1518
-
-
Liliemark, J.1
Albertioni, F.2
Hassan, M.3
Juliusson, G.4
-
30
-
-
7344254620
-
Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukemia
-
Betticher DC, Ratschiller D, Hsu Schmitz S-F, et al. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukemia. Ann Oncol 1998;9:721-726.
-
(1998)
Ann Oncol
, vol.9
, pp. 721-726
-
-
Betticher, D.C.1
Ratschiller, D.2
Hsu Schmitz, S.-F.3
-
31
-
-
33846258434
-
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
-
Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405-411.
-
(2007)
Blood
, vol.109
, pp. 405-411
-
-
Kay, N.E.1
Geyer, S.M.2
Call, T.G.3
-
32
-
-
0037220152
-
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patientswith B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712)
-
Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patientswith B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
-
(2003)
Blood
, vol.101
, pp. 6-14
-
-
Byrd, J.C.1
Peterson, B.L.2
Morrison, V.A.3
-
33
-
-
59149106873
-
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses
-
Lamanna N, Jurcic JG, Noy A, et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009; 27:491-497.
-
(2009)
J Clin Oncol
, vol.27
, pp. 491-497
-
-
Lamanna, N.1
Jurcic, J.G.2
Noy, A.3
-
34
-
-
78650542873
-
Impact of different chemotherapy regimen in comorbid patients with advanced chronic lymphocytic leukemia: Metaanalysis of two phase-III trials of the German CLL Study Group
-
(Abstract 2840)
-
Cramer P, Goede V, Jenke P, Busch R, Hallek M, Eichhorst B. Impact of different chemotherapy regimen in comorbid patients with advanced chronic lymphocytic leukemia: metaanalysis of two phase-III trials of the German CLL Study Group. Blood 2006;108(Suppl. 1):804a (Abstract 2840).
-
(2006)
Blood
, vol.108
, Issue.SUPPL. 1
, pp. 804
-
-
Cramer, P.1
Goede, V.2
Jenke, P.3
Busch, R.4
Hallek, M.5
Eichhorst, B.6
-
35
-
-
0028987180
-
P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
-
Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85: 1580-1589.
-
(1995)
Blood
, vol.85
, pp. 1580-1589
-
-
Döhner, H.1
Fischer, K.2
Bentz, M.3
|